ClinicalTrials.gg
CompletedNCT01044862AMIGOSUpdated Feb 2, 2015Results posted

Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation

A Phase 3 interventional study of Letrozole (aromatase inhibitor) and Clomiphene Citrate in Pregnancy and Unexplained Infertility, sponsored by Yale University. Completed at 14 sites in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2015-02-02.

Sponsored by Yale University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies testing letrozole in Infertility — 2 open to participants now, 3 under way, 2 of them phase 3. Letrozole · Infertility.

Enrollment
2nd of 31
900 · median 131
Started
2010
the only one that year
Phase 3
10 of 31
1 open now
Registered
6th of 31
by date
Lead sponsor
2 of 31
Yale University

Among the 31 studies testing letrozole in Infertility, this one is the 2nd largest by enrollment, is the only one that started in 2010, is one of 10 in phase 3, and was the 6th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

2 of the 31 studies testing letrozole in Infertility are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing letrozole in Infertility, or all of them as a file.
02

Study summary

The objective of this application is to identify a pharmacologic agent which helps couples in whom the female partner ovulates regularly successfully obtain their goal of delivering a healthy child, whose use will result in low rates of multiple gestations. The central hypothesis is that, in infertile ovulatory women undergoing ovarian stimulation (OS) and intrauterine insemination (IUI), the use of aromatase inhibitors (AI) will stimulate the ovaries sufficiently to produce no reduction in the rate of pregnancy, while significantly reducing the numbers of multiple gestational pregnancies that result from stimulation with clomiphene citrate (CC) or follicle stimulating hormone (FSH). The rationale for the proposed research is that reduction of multiple pregnancy rates could significantly reduce maternal and neonatal morbidity and mortality, as well as the cost of healthcare for these individuals and society.

Read the detailed description

Patient Population

The population will consist of 900 women up to and including women ≥18 to ≤40 years years of age (at time of randomization) desirous of conceiving who will be recruited over approximately a two year period from the Reproductive Medicine Network (RMN) clinical sites and possibly from the Specialized Cooperative Center Programs in Reproductive Research (SCCPIR) sites, through public notification programs.

Study Design

This will be a multi-center, prospective, partially blinded clinical trial of gonadotropins vs. clomiphene citrate vs. aromatase inhibitors. The randomization scheme will be coordinated through the data coordination center (DCC) and the randomization will be stratified by each participating site and within each site for ages 18-34 and 35-40.

Treatment

Patients will be randomized to receive either FSH, CC, or an AI according to randomization tables generated by a computer randomization program. Treatment assignments will be blocked by site and age group. Subjects randomized to pill treatment will receive medication in double blinded fashion, receiving one type of pill (overcoated CC or AI). Subjects randomized to injectable medication(FSH) will receive vials of medication.

Primary efficacy parameter

Multiple gestation rate following recruitment of multiple follicular development with an AI, as compared to CC and FSH.

Secondary efficacy parameters

Rate of pregnancy obtained, live birth rate, and time to pregnancy following administration of an aromatase inhibitor, as compared to CC and FSH as well as the live birth rate of multiple gestation pregnancies.

03

Conditions studied

  • Pregnancy
  • Unexplained Infertility

Browse trials for

Keywords

  • Pregnancy
  • Infertility
  • Ovarian stimulation
  • Aromatase inhibitors
  • Follicle Stimulating Hormone
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women ≥18 to ≤40 years of age, with one or more years infertility history, desirous of conceiving, regularly ovulating (defined as 9 or more menses per year), at initiation of participation.
  2. Normal uterine cavity and at least one open fallopian tube confirmed by hysterosalpingography (HSG), sonohysterography, or laparoscopy/hysteroscopy in the last three years preceding enrollment into the study. An uncomplicated intrauterine non-IVF pregnancy and uncomplicated delivery and postpartum course resulting in live birth within the last three years will also serve as sufficient evidence of a patent tube and normal uterine cavity as long as the subject did not have, during the pregnancy or subsequently, risk factors for Asherman's syndrome or tubal disease or other disorder leading to an increased suspicion for intrauterine abnormality or tubal occlusion.
  3. Evidence of ovarian function/reserve as assessed by day 3 (+/-2 days) FSH ≤12 IU/L within one year prior to study initiation.
  4. Normal or corrected thyroid function within one year of study initiation.
  5. Normal prolactin level within one year of study initiation.
  6. In general good health, not taking any medications which could interfere with the study (e.g., FSH, insulin sensitizers).
  7. Ability to have inseminations following hCG administration.
  8. Male partner with total motile sperm in the ejaculate of at least 5 million sperm, within one year of study initiation.

Exclusion criteria

Exclusion Criteria:

  1. Currently pregnant or successful pregnancies within 12 months of initiating participation. Clinical intrauterine miscarriages prior to initiating participation, within ASRM guidelines: subjects over 35 must wait six months, while subjects under 35 must wait 12 months. No exclusion for biochemical pregnancies.
  2. Undiagnosed abnormal uterine bleeding.
  3. Suspicious ovarian mass.
  4. Patients on oral , depo-progestins, or hormonal implants (including Implanon). A two month will be required prior to screening for patients on these agents. Longer washouts may be necessary for certain depot contraceptive forms or implants, especially when the implants are still in place. A one-month washout will be required for patients on oral cyclic progestins.
  5. Known 21-hydroxylase deficiency or other enzyme defect causing congenital adrenal hyperplasia.
  6. Type I or Type II diabetes mellitus, or if receiving antidiabetic medications.
  7. Known significant anemia ( \<10 g/dL).
  8. History of deep venous thrombosis, pulmonary embolus, or cerebrovascular event.
  9. Known heart disease ( Class II or higher).
  10. Known Liver disease (defined as or ALT>2 times normal, or total >2.5 mg/dL).
  11. Known Renal disease (defined as BUN >30 mg/dL or serum creatinine > 1.4 mg/dL).
  12. History of, or suspected cervical carcinoma, endometrial carcinoma or breast carcinoma.
  13. History of alcohol abuse (defined as >14 drinks/week) or binge drinking of ≥ 6 drinks at one time).
  14. Known Cushing's disease.
  15. Known or suspected adrenal or ovarian androgen secreting tumors.
  16. Allergy or to the treatment medications: AI, gonadotropins, CC or hCG.
  17. Couples with previous sterilization procedures (e.g. vasectomy, tubal ligation) which have been reversed.
  18. Patients with untreated poorly controlled hypertension defined as a systolic blood pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures obtained at least 60 minutes apart.
  19. Subjects who have undergone a bariatric surgery procedure in the recent past (\< 12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon.
  20. Known moderate or severe endometriosis
  21. Known polycystic ovarian syndrome as evidenced by anovulation or oligoovulation, hirsutism and/or elevated testosterone levels, and ovarian morphology on ultrasound examination.
  22. Donated semen.
  23. Couples in which either partner is legally married to someone else.
  24. Medical conditions that are contraindications to pregnancy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
900 participants (actual)

Study arms

  • Active comparator
    Aromatase Inhibitors (AI)

    A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.

    Drug: Letrozole (aromatase inhibitor)

  • Active comparator
    Clomiphene Citrate (CC)

    CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.

    Drug: Clomiphene Citrate

  • Active comparator
    Follicle Stimulating Hormone (FSH)

    A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.

    Drug: Follicle Stimulating Hormone (gonadotropin)

Interventions

  • DrugLetrozoleStudies of LetrozoleLetrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.

  • DrugClomipheneStudies of ClomipheneClomiphene pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.

  • DrugFollicle Stimulating HormoneStudies of Follicle Stimulating HormoneFollicle Stimulating Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.

06

What researchers measure

Primary outcomes

  1. Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.

    Time frame: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

Secondary outcomes

  1. Rate of Pregnancy Obtained

    Time frame: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

  2. Time to Pregnancy

    Time frame: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

  3. Live Birth Rate

    Time frame: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

07

Results

Posted Feb 2, 2015

Participant flow

Participant flow — Overall Study
MilestoneAromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)
Started299300301
Completed246251249
Not completed534952

Outcome measures

PrimaryMultiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.
Time frame:
Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks
Reported as:
Number · number of multiples
Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.
number of multiplesAromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)
Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.9834
SecondaryRate of Pregnancy Obtained
Time frame:
Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks
Reported as:
Number · participants
Rate of Pregnancy Obtained
participantsAromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)
Rate of Pregnancy Obtained85106140
SecondaryTime to Pregnancy
Time frame:
Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks
Reported as:
Mean · days
Time to Pregnancy
daysAromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)
Time to Pregnancy67.2 ± 55.667.4 ± 49.862.3 ± 43.8
SecondaryLive Birth Rate
Time frame:
Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks
Reported as:
Number · participants
Live Birth Rate
participantsAromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)
Live Birth Rate567097

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aromatase Inhibitors (AI)—11/291 (3.8%)218/291 (74.9%)
Clomiphene Citrate (CC)—12/298 (4%)214/298 (71.8%)
Follicle Stimulating Hormone (FSH)—25/297 (8.4%)217/297 (73.1%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventAromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)
Ectopic pregnancyPregnancy, puerperium and perinatal conditions5/2915/29811/297
Congenital anomalyCongenital, familial and genetic disorders2/2913/2983/297
HyperemesisGastrointestinal disorders0/2910/2982/297
Pregnancy of Unknown LocationPregnancy, puerperium and perinatal conditions0/2912/2981/297
Hemorrhagic HematomaInjury, poisoning and procedural complications1/2910/2980/297
HypertensionCardiac disorders1/2911/2980/297
Hospitalization due to shorness of breath; pulmonary edemaRespiratory, thoracic and mediastinal disorders1/2910/2980/297
Neonatal DeathGeneral disorders1/2910/2980/297
Presumed PyelonephritisRenal and urinary disorders0/2910/2981/297
Pyosalpinx Post IUIReproductive system and breast disorders0/2910/2981/297
Most frequent other events
Most frequent other events
EventAromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)
HeadacheNervous system disorders122/291104/29889/297
Hot FlashesEndocrine disorders49/29192/29825/297
Abdominal BloatingGastrointestinal disorders54/29150/29881/297
Breast PainReproductive system and breast disorders26/29119/29865/297
Injection Site ReactionGeneral disorders9/2916/29832/297
ConstipationGastrointestinal disorders8/29128/2986/297
Joint/Limb painMusculoskeletal and connective tissue disorders17/2918/2985/297

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)Total
Mean32.2 ± 4.332.0 ± 4.632.2 ± 4.132.2 ± 4.4
Sex: Female, Male
Sex: Female, Male(Participants)Aromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)Total
Female299300301900
Male0000
Region of Enrollment
Region of Enrollment(participants)Aromatase Inhibitors (AI)Clomiphene Citrate (CC)Follicle Stimulating Hormone (FSH)Total
United States299300301900
08

Study locations

14 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35249-7333, United States
  • University of California, San Francisco
    San Francisco, California 94115, United States
  • Stanford University Medical Center
    Stanford, California 94305-5317, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Yale University
    New Haven, Connecticut 06511, United States
  • University of Michigan
    Ann Arbor, Michigan 48108, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • University of Medicine and Dentistry of New Jersey
    Newark, New Jersey 07601, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28232-2861, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Pennsylvania State University College of Medicine
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78207, United States
  • University of Vermont
    Burlington, Vermont 05405, United States
09

References and documents

Publications

  • Gavrizi SZ, Arya S, Peck JD, Knudtson JF, Diamond MP, Wild RA, Hansen KR. High-sensitivity C-reactive protein levels and pregnancy outcomes in women with unexplained infertility after ovarian stimulation with intrauterine insemination in a multicenter trial. F S Rep. 2022 Jan 11;3(1):57-62. doi: 10.1016/j.xfre.2022.01.001. eCollection 2022 Mar. PubMed 35386508 ↗
  • Souter I, Sun F, Zhang H, Diamond MP, Legro RS, Wild RA, Hansen KR, Santoro N; Eunice Kennedy Schriver National Institute of Child Health and Human Development Reproductive Medicine Network. A personalized medicine approach to ovulation induction/ovarian stimulation: development of a predictive model and online calculator from level-I evidence. Fertil Steril. 2022 Feb;117(2):408-418. doi: 10.1016/j.fertnstert.2021.10.024. PubMed 35125179 ↗
  • Eisenberg E, Legro RS, Diamond MP, Huang H, O'Brien LM, Smith YR, Coutifaris C, Hansen KR, Santoro N, Zhang H. Sleep Habits of Women With Infertility. J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4414-e4426. doi: 10.1210/clinem/dgab474. PubMed 34180998 ↗
  • Engmann L, Sun F, Legro RS, Diamond MP, Zhang H, Santoro N; Reproductive Medicine Network. Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth. Hum Reprod. 2020 Dec 1;35(12):2819-2831. doi: 10.1093/humrep/deaa232. PubMed 33190149 ↗
  • Quaas AM, Gavrizi SZ, Peck JD, Diamond MP, Legro RS, Robinson RD, Casson P, Christman GM, Zhang H, Hansen KR; Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Medicine Network. Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes. Fertil Steril. 2021 Jan;115(1):213-220. doi: 10.1016/j.fertnstert.2020.07.030. Epub 2020 Sep 21. PubMed 32972733 ↗
  • Kaing A, Jaswa EA, Diamond MP, Legro RS, Cedars MI, Huddleston HG. Highly elevated level of antimullerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction. Fertil Steril. 2021 Feb;115(2):438-446. doi: 10.1016/j.fertnstert.2020.06.015. Epub 2020 Sep 1. PubMed 32883514 ↗
  • Wang ET, Diamond MP, Alvero R, Casson P, Christman GM, Coutifaris C, Hansen KR, Sun F, Legro RS, Robinson RD, Usadi RS, Pisarska MD, Santoro NF, Zhang H; National Institute of Child Health and Human Development (NICHD) Reproductive Medicine Network. Androgenicity and fertility treatment in women with unexplained infertility. Fertil Steril. 2020 Mar;113(3):636-641. doi: 10.1016/j.fertnstert.2019.10.034. PubMed 32192596 ↗
  • Trussell JC, Coward RM, Santoro N, Stetter C, Kunselman A, Diamond MP, Hansen KR, Krawetz SA, Legro RS, Heisenleder D, Smith J, Steiner A, Wild R, Casson P, Coutifaris C, Alvero RR, Robinson RB, Christman G, Patrizio P, Zhang H, Lindgren MC; Reproductive Medicine Network. Association between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population. Fertil Steril. 2019 Jun;111(6):1129-1134. doi: 10.1016/j.fertnstert.2019.01.034. Epub 2019 Apr 12. PubMed 30982604 ↗
  • Barrett ES, Vitek W, Mbowe O, Thurston SW, Legro RS, Alvero R, Baker V, Bates GW, Casson P, Coutifaris C, Eisenberg E, Hansen K, Krawetz S, Robinson R, Rosen M, Usadi R, Zhang H, Santoro N, Diamond M. Allostatic load, a measure of chronic physiological stress, is associated with pregnancy outcomes, but not fertility, among women with unexplained infertility. Hum Reprod. 2018 Sep 1;33(9):1757-1766. doi: 10.1093/humrep/dey261. PubMed 30085177 ↗
  • Butts SF, Seifer DB, Koelper N, Senapati S, Sammel MD, Hoofnagle AN, Kelly A, Krawetz SA, Santoro N, Zhang H, Diamond MP, Legro RS; Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Medicine Network. Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility. J Clin Endocrinol Metab. 2019 Feb 1;104(2):369-378. doi: 10.1210/jc.2018-00750. PubMed 30085176 ↗
  • Evans-Hoeker EA, Eisenberg E, Diamond MP, Legro RS, Alvero R, Coutifaris C, Casson PR, Christman GM, Hansen KR, Zhang H, Santoro N, Steiner AZ; Reproductive Medicine Network. Major depression, antidepressant use, and male and female fertility. Fertil Steril. 2018 May;109(5):879-887. doi: 10.1016/j.fertnstert.2018.01.029. PubMed 29778387 ↗
  • Hansen KR, Eisenberg E, Baker V, Hill MJ, Chen S, Talken S, Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Santoro N, Zhang H, Wild RA; NICHD Reproductive Medicine Network. Midluteal Progesterone: A Marker of Treatment Outcomes in Couples With Unexplained Infertility. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2743-2751. doi: 10.1210/jc.2018-00642. PubMed 29767754 ↗
  • Seungdamrong A, Steiner AZ, Gracia CR, Legro RS, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Robinson RD, Huang H, Alvero R, Hansen KR, Jin S, Eisenberg E, Zhang H, Santoro N; Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Medicine Network. Preconceptional antithyroid peroxidase antibodies, but not thyroid-stimulating hormone, are associated with decreased live birth rates in infertile women. Fertil Steril. 2017 Oct 25:S0015-0282(17)31748-X. doi: 10.1016/j.fertnstert.2017.08.026. Online ahead of print. PubMed 29102040 ↗
  • Styer AK, Jin S, Liu D, Wang B, Polotsky AJ, Christianson MS, Vitek W, Engmann L, Hansen K, Wild R, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Christy A, Diamond MP, Eisenberg E, Zhang H, Santoro N; National Institute of Child Health and Human Development Reproductive Medicine Network. Association of uterine fibroids and pregnancy outcomes after ovarian stimulation-intrauterine insemination for unexplained infertility. Fertil Steril. 2017 Mar;107(3):756-762.e3. doi: 10.1016/j.fertnstert.2016.12.012. Epub 2017 Jan 12. PubMed 28089575 ↗
  • Santoro N, Eisenberg E, Trussell JC, Craig LB, Gracia C, Huang H, Alvero R, Casson P, Christman G, Coutifaris C, Diamond M, Jin S, Legro RS, Robinson RD, Schlaff WD, Zhang H; Reproductive Medicine Network Investigators. Fertility-related quality of life from two RCT cohorts with infertility: unexplained infertility and polycystic ovary syndrome. Hum Reprod. 2016 Oct;31(10):2268-79. doi: 10.1093/humrep/dew175. Epub 2016 Jul 7. PubMed 27402910 ↗
  • Hansen KR, He AL, Styer AK, Wild RA, Butts S, Engmann L, Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Huang H, Santoro N, Eisenberg E, Zhang H; Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Medicine Network. Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation-intrauterine insemination. Fertil Steril. 2016 Jun;105(6):1575-1583.e2. doi: 10.1016/j.fertnstert.2016.02.020. Epub 2016 Mar 3. PubMed 26949110 ↗
  • Steiner AZ, Diamond MP, Legro RS, Schlaff WD, Barnhart KT, Casson PR, Christman GM, Alvero R, Hansen KR, Geisler WM, Thomas T, Santoro N, Zhang H, Eisenberg E; Reproductive Medicine Network. Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertil Steril. 2015 Dec;104(6):1522-6. doi: 10.1016/j.fertnstert.2015.08.022. Epub 2015 Sep 25. PubMed 26413816 ↗
  • Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Ager J, Huang H, Hansen KR, Baker V, Usadi R, Seungdamrong A, Bates GW, Rosen RM, Haisenleder D, Krawetz SA, Barnhart K, Trussell JC, Ohl D, Jin Y, Santoro N, Eisenberg E, Zhang H; NICHD Reproductive Medicine Network. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. N Engl J Med. 2015 Sep 24;373(13):1230-40. doi: 10.1056/NEJMoa1414827. PubMed 26398071 ↗
  • Kuang H, Jin S, Thomas T, Engmann L, Hansen KR, Coutifaris C, Casson P, Christman G, Alvero R, Santoro N, Eisenberg E, Diamond MP, Legro RS, Zhang H; Reproductive Medicine Network. Predictors of participant retention in infertility treatment trials. Fertil Steril. 2015 Nov;104(5):1236-43.e1-2. doi: 10.1016/j.fertnstert.2015.08.001. Epub 2015 Sep 3. PubMed 26354094 ↗
  • Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Ager J, Huang H, Hansen KR, Baker V, Usadi R, Seungdamrong A, Bates GW, Rosen RM, Haisonleder D, Krawetz SA, Barnhart K, Trussell JC, Jin Y, Santoro N, Eisenberg E, Zhang H; National Institute of Child Health and Human Development (NICHD) Reproductive Medicine Network. Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics. Fertil Steril. 2015 Apr;103(4):962-973.e4. doi: 10.1016/j.fertnstert.2014.12.130. Epub 2015 Feb 20. PubMed 25707331 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Oct 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2010
First posted
Jan 8, 2010
Start
Jun 2010
Primary completionActual
Oct 2013
CompletionActual
Mar 2014
Results first posted
Feb 2, 2015
Last update
Feb 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01044862
Lead sponsor
Yale University
Responsible party
Heping Zhang (Principal Investigator, Yale University) — Principal investigator
First posted
Jan 8, 2010
Start date
Jun 2010
Primary completion
Oct 2013
Completion
Mar 2014
Results posted
Feb 2, 2015
Last update
Feb 2, 2015

Study contacts

Esther Eisenberg, MD, MPH
study director · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Nanette Santoro, MD
study chair · Albert Einstein College of Medicine
Michael Diamond, MD
principal investigator · Wayne State University
Richard Legro, MD
study director · Pennsylvania State University College of Medicine
William Schlaff, MD
study director · University of Colorado Denver Health Science Center
Gregory Christman, MD
study director · University of Michigan
Christos Coutifaris, MD
study director · University of Pennsylvania
Robert Brzyski, MD, PhD
study director · The University of Texas Health Science Center at San Antonio
Peter Casson, MD
study director · University of Vermont
Heping Zhang, PhD
study director · Yale University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Letrozole · Clomiphene · Follicle Stimulating Hormone

Start the discussion